Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elevate-CKD phase 3 study of elecoglipron in adults with chronic kidney disease
CTR20264015Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elecoglipron in chronic kidney disease (CKD), sponsored by AstraZeneca. Started Oct 2026; status: active.
02
Drugs
elecoglipron
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20264015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264015.